Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.39 |
| ▸ | ACSL1 | P33121 | 8/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 2/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | ACSL3 | O95573 | 1/20 | 0.36 |
| ▸ | ACSL6 | Q9UKU0 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10186440 | 0.94 | PTGDR2 (0.38) | DGAT1ACSL1PTGDR2HRH3MMP12 | |
| SCHEMBL10186189 | 0.92 | HRH3 (0.42) | DGAT1ACSL1HRH3MMP12 | |
| SCHEMBL10184950 | 0.91 | DGAT1 (0.46) | DGAT1HRH3MMP12 | |
| SCHEMBL10185146 | 0.90 | MAPK1 (0.42) | DGAT1ACSL1PTGDR2HRH3CCR3 | |
| SCHEMBL10186424 | 0.86 | ALDH1A1 (0.46) | DGAT1ACSL1PTGDR2 | |
| SCHEMBL10185353 | 0.85 | PTGDR2 (0.40) | DGAT1ACSL1PTGDR2HRH3CCR3 | |
| SCHEMBL10185105 | 0.85 | CCR3 (0.49) | ACSL1PTGDR2CCR3 | |
| SCHEMBL10185364 | 0.85 | CCR3 (0.44) | ACSL1PTGDR2HRH3CCR3 | |
| SCHEMBL10186162 | 0.85 | CCR3 (0.44) | DGAT1ACSL1PTGDR2HRH3CCR3 | |
| SCHEMBL10186172 | 0.83 | CHRM1 (0.47) | ACSL1PTGDR2CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | DGAT1 1/4885ACSL1 508/4885PTGDR2 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.